TransCode Therapeutics has announced new data supporting the use of TTX-MC138 for the treatment of metastatic breast cancer. The RNA oncology company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, described as the master regulator of cancer progression in a number of advanced solid tumors including breast cancer. In a preclinical model of pancreatic adenocarcinoma, administration of TTX-MC138 resulted in complete responses without recurrence in 40% of treated animals. TransCode recently received FDA and IRB approval for a first-in-human clinical trial with TTX-MC138 in patients with advanced solid cancers.
TransCode believes that these findings are significant because cancer stem cells have long been known to play an important role in cancer initiation, metastasis, recurrence and resistance to therapy. Therefore, inhibiting the tumor-promoting capacity of these cells using TTX-MC138 could improve outcomes in patients with breast cancer that is recurrent and resistant to treatment.
The study was published in the Journal of Clinical Oncology and presented at the 2023 Annual Meeting of the American